Four Decades for Justice
On September 30, 2014, Johnson & Johnson announced a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. Cravath represented Johnson & Johnson in the transaction. The closing is subject to clearance under the Hart‑Scott‑Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the fourth quarter of 2014.
The Cravath team was led by partner Robert I. Townsend III on M&A matters; partner Eric W. Hilfers and associates Jarrett R. Hoffman and Matthew J. Bobby on executive compensation and benefits matters; and partner David J. Kappos and associate Benjamin D. Landry on intellectual property matters. Adam J. Gross also worked on M&A matters.
Deals & Cases
November 01, 2022
On November 1, 2022, Johnson & Johnson and Abiomed, a leader in breakthrough heart, lung and kidney support technologies, announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. Cravath is representing Johnson & Johnson in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.